Novo Nordisk to cut 9,000 jobs globally
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Subscribe To Our Newsletter & Stay Updated